Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

DA-EPOCH-R improves the outcome over that of R-CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high-risk IPI, but not for double expressor lymphoma.

Zhang XY, Liang JH, Wang L, Zhu HY, Wu W, Cao L, Fan L, Li JY, Xu W.

J Cancer Res Clin Oncol. 2018 Oct 16. doi: 10.1007/s00432-018-2771-9. [Epub ahead of print]

PMID:
30327941
2.

A comparison of R-EPOCH and R-CHOP as a first-line regimen in de novo DLBCL patients with high Ki-67 expression in a single institution.

Huang JJ, Xia Y, Wang Y, Liu PP, Bi XW, Sun P, Lin TY, Jiang WQ, Li ZM.

Oncotarget. 2016 Jul 5;7(27):41242-41250. doi: 10.18632/oncotarget.9271.

3.

Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers.

Wilson WH, Dunleavy K, Pittaluga S, Hegde U, Grant N, Steinberg SM, Raffeld M, Gutierrez M, Chabner BA, Staudt L, Jaffe ES, Janik JE.

J Clin Oncol. 2008 Jun 1;26(16):2717-24. doi: 10.1200/JCO.2007.13.1391. Epub 2008 Mar 31.

4.

Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.

Nowakowski GS, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD, Thompson CA, Rivera CE, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Gascoyne RD, Habermann TM, Witzig TE.

J Clin Oncol. 2015 Jan 20;33(3):251-7. doi: 10.1200/JCO.2014.55.5714. Epub 2014 Aug 18.

PMID:
25135992
5.

Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.

Molina TJ, Canioni D, Copie-Bergman C, Recher C, Brière J, Haioun C, Berger F, Fermé C, Copin MC, Casasnovas O, Thieblemont C, Petrella T, Leroy K, Salles G, Fabiani B, Morschauser F, Mounier N, Coiffier B, Jardin F, Gaulard P, Jais JP, Tilly H.

J Clin Oncol. 2014 Dec 10;32(35):3996-4003. doi: 10.1200/JCO.2013.54.9493. Epub 2014 Nov 10.

PMID:
25385729
6.

Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.

Li X, Liu Z, Cao J, Hong X, Wang J, Chen F, Wang C, Zou S, Li J, Shen Z.

Ann Hematol. 2012 Jun;91(6):837-45. doi: 10.1007/s00277-011-1375-0. Epub 2011 Dec 9.

PMID:
22160255
7.

High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy.

Li ZM, Huang JJ, Xia Y, Zhu YJ, Zhao W, Wei WX, Jiang WQ, Lin TY, Huang HQ, Guan ZZ.

Eur J Haematol. 2012 Jun;88(6):510-7. doi: 10.1111/j.1600-0609.2012.01778.x. Epub 2012 Mar 27.

PMID:
22413767
8.

Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients.

Pejša V, Prka Ž, Lucijanić M, Mitrović Z, Piršić M, Jakšić O, Ajduković R, Kušec R.

Croat Med J. 2017 Feb 28;58(1):40-48.

9.

Short-term efficacy of rituximab-CHOP and CHOP regimens on two subtypes of diffuse large B-cell lymphoma.

Xia Y, Li ZM, Shi YX, Xia ZJ, Jiang WQ, Huang HQ.

Ai Zheng. 2009 Feb;28(2):146-9. Epub 2009 Feb 15.

PMID:
19550126
10.

Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.

Abdelhamid T, Samra M, Ramadan H, Mehessin M, Mokhtar N.

J Egypt Natl Canc Inst. 2011 Mar;23(1):17-24. doi: 10.1016/j.jnci.2011.07.003. Epub 2011 Sep 8.

11.

[Influence of transplantation and some clinical factors on prognosis of patients with diffuse large B-cell lymphoma].

Zhao SX, Han Y, Zhu Q, Wang Q, Zhang WJ, Chen XC, Sun AN, Jin ZM, Qiu HY, Tang XW, Fu ZZ, He GS, Miao M, Ma X, Wu DP.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Jun;21(3):623-7. doi: 10.7534/j.issn.1009-2137.2013.03.017. Chinese.

PMID:
23815910
12.

Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.

Leonard JP, Kolibaba KS, Reeves JA, Tulpule A, Flinn IW, Kolevska T, Robles R, Flowers CR, Collins R, DiBella NJ, Papish SW, Venugopal P, Horodner A, Tabatabai A, Hajdenberg J, Park J, Neuwirth R, Mulligan G, Suryanarayan K, Esseltine DL, de Vos S.

J Clin Oncol. 2017 Nov 1;35(31):3538-3546. doi: 10.1200/JCO.2017.73.2784. Epub 2017 Sep 1.

PMID:
28862883
13.

Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.

Xu-Monette ZY, Li L, Byrd JC, Jabbar KJ, Manyam GC, Maria de Winde C, van den Brand M, Tzankov A, Visco C, Wang J, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Winter JN, Wang M, Hagemeister FB, Piris MA, Han van Krieken J, Medeiros LJ, Li Y, van Spriel AB, Young KH.

Blood. 2016 Dec 29;128(26):3083-3100. doi: 10.1182/blood-2016-05-715094. Epub 2016 Oct 19.

14.

[Efficacy of surgery and rituximab in primary gastric diffuse large B-cell lymphoma].

Huang HW, Jiang YB, Fu TW, Xu T, Chen XC, Jin ZM, Wu DP.

Zhonghua Xue Ye Xue Za Zhi. 2016 Jul;37(7):602-6. doi: 10.3760/cma.j.issn.0253-2727.2016.07.012. Chinese.

PMID:
27535862
15.

BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.

Iqbal J, Meyer PN, Smith LM, Johnson NA, Vose JM, Greiner TC, Connors JM, Staudt LM, Rimsza L, Jaffe E, Rosenwald A, Ott G, Delabie J, Campo E, Braziel RM, Cook JR, Tubbs RR, Gascoyne RD, Armitage JO, Weisenburger DD, Chan WC.

Clin Cancer Res. 2011 Dec 15;17(24):7785-95. doi: 10.1158/1078-0432.CCR-11-0267. Epub 2011 Sep 20.

16.

Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens.

Goto N, Tsurumi H, Kasahara S, Kanemura N, Hara T, Yasuda I, Shimizu M, Murakami N, Sawada M, Yamada T, Takemura M, Seishima M, Kito Y, Takami T, Moriwaki H.

Eur J Haematol. 2011 Sep;87(3):217-27. doi: 10.1111/j.1600-0609.2011.01649.x. Epub 2011 Jul 26.

PMID:
21575062
17.

Prediction of survival by applying current prognostic models in diffuse large B-cell lymphoma treated with R-CHOP followed by autologous transplantation.

Lee HG, Kim SY, Kim I, Kim YK, Kim JA, Kim YS, Lee HS, Park J, Kim SJ, Shim H, Eom HS, Park BB, Lee J, Park SK, Cheong JW, Park KW.

Blood Res. 2015 Sep;50(3):160-6. doi: 10.5045/br.2015.50.3.160. Epub 2015 Sep 22.

18.

[Clinical Efficacy of EPOCH±R Followed by DICE±R Regimen for Primary Breast Diffuse Large B-Cell Lymphoma].

Dong LH, Chen JL, Gao X, Li GP, Li YF, Song YP, Wei XD.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017 Jun;25(3):766-771. doi: 10.7534/j.issn.1009-2137.2017.03.023. Chinese.

PMID:
28641632
19.
20.

[The prognostic value of the international prognostic index, the national comprehensive cancer network IPI and the age-adjusted IPI in diffuse large B cell lymphoma].

Song JL, Wei XL, Zhang YK, Hao XX, Huang WM, Wei Q, Wei YQ, Feng R.

Zhonghua Xue Ye Xue Za Zhi. 2018 Sep 14;39(9):739-744. doi: 10.3760/cma.j.issn.0253-2727.2018.09.007. Chinese.

PMID:
30369184

Supplemental Content

Support Center